Patrick Neven
Artificial Intelligence · 2011–2021
A researcher in the Science corpus: 9 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Artificial Intelligence — 8 citations into it; #30,546 of 35,345 by trust here, #25,809 by citations
Whom Patrick Neven trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Patrick Neven overall
Papers from Patrick Neven's perspective
Ordered by how strongly the researchers Patrick Neven trusts endorse each paper. Same corpus, a different order for every researcher.
- An Introduction To Compressive Sampling
- The Elements of Statistical Learning
- Statistical Learning Theory
- Enhancing Sparsity by Reweighted ℓ1 Minimization
- Nonlinear total variation based noise removal algorithms
- Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis
- The diagnostic odds ratio: a single indicator of test performance. (Journal of Clinical Epidemiology)
- Regression Modeling Strategies (Technometrics)
- Least Squares Support Vector Machine Classifiers
- Rule extraction from support vector machines: A review
Their papers
- Risk group detection and survival function estimation for interval coded survival methods (2013) — 5 citations
- A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer (2021) — 664 citations
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020) — 820 citations
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019) — 846 citations
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. (2019) — 664 citations
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. (2018) — 925 citations
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017) — 1,439 citations
- A Mathematical Model for Interpretable Clinical Decision Support with Applications in Gynecology (2012) — 39 citations
- Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. (2011) — 700 citations